We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.
The management of hepatitis B virus (HBV) / HIV-1 co-infected patients starting their first HAART regimen : treating two infections at the price of one drug ? / M. Puoti, A. Cozzi-Lepri, F. Ancarani, R. Bruno, S. Ambu, T. Ferraro, P. Tundo, T. Santantonio, M. Toti, M. Bonasso, A. D’Arminio Monforte, HepaI.Co.N.A. Study Group. - In: ANTIVIRAL THERAPY. - ISSN 1359-6535. - 9:5(2004), pp. 811-817.
The management of hepatitis B virus (HBV) / HIV-1 co-infected patients starting their first HAART regimen : treating two infections at the price of one drug ?
A. D’Arminio MonforteUltimo
;
2004
Abstract
We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [-81.1 mU/ml mean difference; 95% confidence intervals (95% CI): -30.3; -131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01-0.38, P=0.002] than those starting a lamivudine sparing-regimen.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
